Adaptive Biotechnologies banks $195M for NGS; Juno bets $13M on Fate's platform;

@FierceBiotech: Ebola outbreak spurs a new antibody screening project at Theraclone. More from FierceBiotechResearch | Follow @FierceBiotech

@JohnCFierce: If Big Pharma takes over Kendall Sq the biotechs are going to have to move somewhere else. What's the new Brooklyn in Boston? | Follow @JohnCFierce

> Juno Therapeutics ($JUNO) has partnered up with Fate Therapeutics ($FATE) in a four-year research collaboration combining the former's T cell technology with the latter's small-molecule R&D platform. Juno will pay its partner $5 million up front and buy $8 million worth of Fate's shares, promising as much as $50 million for each resulting product. Fate's shares jumped almost 40% on the deal. Release

> Gene sequencing upstart Adaptive Biotechnologies raised $195 million in Series F financing, cash that will help support its efforts to decode targets for T cell therapy and expand the use of its platform technology. More

> GlaxoSmithKline ($GSK) has nixed its plans to sell off a stake of its ViiV Healthcare in an IPO, deciding to hold on to its share of a business co-owned with Pfizer ($PFE) and Shionogi. News

Medical Device News

@FierceMedDev: ICYMI yesterday: Abiomed gains on strong Impella revenue, with U.S. sales ramp to come after recent FDA approval. Article | Follow @FierceMedDev

@EmilyWFierce: Mayne Pharma beefs up U.S. sales ops to revive acne-fighter Doryx. FiercePharmaMarketing report | Follow @EmilyWFierce

> Dozens of hospitals to deploy IBM's Watson computer in fight against cancer. Story

> EndoChoice files for up to $115M IPO to back its wider-view Fuse endoscopy system. Article

Pharma News

@FiercePharma: It's all about that data as IBM Watson Health teams up with J&J, Cleveland Clinic and more. Article | Follow @FiercePharma

@EricPFierce: MHRA concerned with lack of testing by Relonchem , which is owned by India's Marksans Pharma. Report | Follow @EricPFierce

@CarlyHFierce: ICYMI: Merck or Merck KGaA? German Merck beefs up branding to (hopefully) end confusion. Article | Follow @CarlyHFierce

> Embattled GSK scraps ViiV spinoff as pharma revenues tumble. Article

> Caforio takes CEO role as BMS faces tough year with promising new drugs. Report

Biotech Research News

> Scientists highlight link between diabetes and Alzheimer's. Item

> Microparticles amp up the effect of breast cancer vaccines. More

> Johns Hopkins team finds a new drug target for diabetes. Story

> UNC researchers hijack natural 'bubbles' to transport Parkinson's med. Article

> Rodent study once again spotlights role of arginase in hypertension. Report

Diagnostics News

> Abbott grabs FDA OK for early pregnancy blood test. Report

> Myriad Genetics stumbles as rivals flood BRCA market. More

> OpGen sees its shares fall 20% in IPO. Story

> Agilent acquires maker of software for diagnostics laboratories. Article

> RainDance Technologies and Pacific Biosciences partner for whole genome assembly. Item

Pharma Marketing News

> GSK's U.S. Advair sales plummet 22% in Q1--and that's without generics. Item

> The Q1 drug launch scorecard, starring Sanofi, Lilly, Pfizer, Gilead, Merck and more. Report

> Merck or Merck KGaA? German Merck beefs up branding to (hopefully) end confusion. More

> Mayne Pharma bolsters U.S. sales ops to revive acne-fighter Doryx. Article

> It's all about that data as IBM Watson Health teams up with J&J, Cleveland Clinic and more. Story

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.